辅助化疗XELOX方案与FOLFOX方案在Ⅱ～Ⅲ期结肠癌中的应用比较  

Comparison of adjuvant chemotherapy treated with XELOX or FOLFOX regimen in patients with stage Ⅱ ～ Ⅲ colon cancer

作　　者：毛英[1] 刘黎[1] 张匠 骆雯[1] 董华琼[1] MAO Ying;LIU Li;ZHANG Jiang;LUO Wen;DONG Hua-qiong(Department of Oncology,Suining Central Hospital,Suining 629000,China)

机构地区：[1]四川省遂宁市中心医院肿瘤科,四川遂宁629000

出　　处：《实用医院临床杂志》2018年第6期48-52,共5页Practical Journal of Clinical Medicine

摘　　要：目的比较辅助化疗XELOX方案与FOLFOX方案在Ⅱ～Ⅲ期结肠癌患者的临床疗效、不良反应及生活质量的差异。方法选取2011年1月至2013年1月我院行根治性手术的120例Ⅱ～Ⅲ期结肠癌患者临床资料,其中69例接受XELOX化疗方案,51例接受FOLFOX化疗方案。比较两组患者5年无病生存率、5年生存率、不良反应及生存质量的差异。结果XELOX组与FOLFOX组患者的5年无病生存率、5年生存率比较,差异无统计学意义(P> 0. 05)。与XELOX组比较,FOLFOX组神经毒性、腹泻、白细胞减少、粒细胞减少、血小板减少、口腔黏膜炎的发生率较低,手足综合征的发生率较高,差异有统计学意义(P <0. 05)。两组患者在化疗前及化疗后的情绪状况、功能状况、身体状况、社会/家庭状况、总体生存质量等差异均无统计学意义(P> 0. 05)。结论辅助化疗XELOX方案与FOLFOX方案在Ⅱ～Ⅲ期结肠癌患者术后5年无病生存率、5年生存率及生活质量无明显差异。但XELOX方案不良反应更少,患者的依从性与耐受性更好。To compare the differences in clinical efficacy,adverse reactions and quality of life in patients with stage II and III colon cancer treated with XELOX or FOLFOX regimens.We collected clinical data of 120 colon cancer patients who underwent radical surgery in our hospital from January 2011 to January 2013.Of these patients,69 patients received XELOX chemotherapy(XELOX group)and 51 patients received FOLFOX chemotherapy(FOLFOX group).The 5-year disease-free survival rate,5-year survival rate,adverse reactions and quality of life were compared between the two groups.There was no statistical difference in 5-year disease-free survival rates and 5-year survival rate between the two groups(P>0.05).The incidence of neurotoxicity,diarrhea,leukopenia,granulocytopenia,thrombocytopenia and oral mucositis as well as hand-foot syndrome in the FOLFOX group was higher than those in the XELOX group(P<0.05).There were no statistically significant difference in emotional status,functional status,physical status,social/family status,and overall quality of life between the two groups before and after chemotherapy(P>0.05).For patients with stage II and III colon cancer,there is no significant difference between XELOX and FOLFOX in improving postoperative 5-year disease-free survival rate,5-year survival rate,and quality of life.However,adverse reactions of XELOX were fewer,and compliance and tolerance of patients were better.

关 键 词：结肠癌 卡培他滨 奥沙利铂 氟尿嘧啶 

分 类 号：R735.3[医药卫生—肿瘤]